Braveheart Bio (NASDAQ:BRVE) Stock Keeps Overweight Rating at Cantor Fitzgerald

Braveheart Bio (NASDAQ:BRVE)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $40.00 price objective on the stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 90.11% from the company’s previous close.

BRVE has been the topic of several other reports. The Goldman Sachs Group initiated coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 price objective for the company. TD Cowen began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating for the company. Jefferies Financial Group began coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective for the company. Finally, Zacks Research raised Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Braveheart Bio Stock Up 3.8%

Shares of Braveheart Bio stock traded up $0.77 during trading hours on Tuesday, reaching $21.04. 224,146 shares of the stock traded hands, compared to its average volume of 460,808. Braveheart Bio has a one year low of $17.86 and a one year high of $32.00. The company has a market capitalization of $1.89 billion and a price-to-earnings ratio of -8.38. The business’s 50 day moving average is $24.31.

Braveheart Bio (NASDAQ:BRVE) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, sell-side analysts expect that Braveheart Bio will post -1.48 EPS for the current year.

Insiders Place Their Bets

In other news, Director Christopher Viehbacher acquired 83,333 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,499,994.00. Following the completion of the purchase, the director directly owned 609,519 shares in the company, valued at approximately $10,971,342. This trade represents a 15.84% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc acquired 1,940,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the transaction, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.